((自动化翻译由路透提供，请见免责声明 ))
9月30日 - ** 药物开发商NeuroBo Pharmaceuticals 股价盘前上涨3.3%至3.43美元
** 该公司称， (link)，在对45名肥胖但身体健康的人进行的早期研究中，发现其肥胖症药物安全、耐受性良好，没有产生任何严重不良反应
** 研究的主要目的是通过监测不良事件来评估药物的安全性和耐受性
** 接受治疗的 5 名受试者报告了不良反应，而安慰剂组只有 3 名受试者--NRBO 称
** 截至上一交易日收盘，股价累计下跌 10.2
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.